Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens
Authors:
- 1 February 2014
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 32 (2) , 70-79
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesOncogene, 2010
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate CancerCancer Research, 2009
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBritish Journal of Cancer, 2009
- Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylationProceedings of the National Academy of Sciences, 2007
- The role of Src in prostate cancerAnnals of Oncology, 2007